DCVC Bio
Overview
DCVC Bio is a venture capital firm that invests in early-stage life science companies leveraging deep-tech approaches. Founded in 2018, the firm focuses on therapeutics platforms, companies improving agriculture and food systems, and industrial biotechnologies. Their investment team comprises experts in genetics, chemistry, molecular biology, agriculture, industrial fermentation, and AI, combining scientific acumen with decades of operational management experience. The firm's strategy centers on supporting foundational initiatives that utilize fundamental science and deep tech to solve complex problems. They are committed to using biology to create a more just, flourishing, and sustainable world. DCVC Bio seeks out and supports companies that can bring breakthrough medicines to the clinic or commercialize novel life sciences products. DCVC Bio has made 60 investments, with notable exits including AbCellera, Chroma Medicine, and BioPhero. Their portfolio includes companies like Elo Life Systems, MycoWorks, and Sabanto, reflecting their diverse interests in biotechnology and life sciences. The firm closed its third fund, DCVC Bio III, at $400 million in October 2024, underscoring its commitment to advancing deep-tech innovations in the life sciences sector.
Investment Focus
- Companies leveraging deep-tech approaches in life sciences
- Early-stage ventures
Portfolio Companies
Reach DCVC Bio directly
Verified work email, phone and LinkedIn for the full team — one spreadsheet, one payment, yours to keep.
Unlock full contacts →Frequently asked questions about DCVC Bio
What sectors does DCVC Bio invest in?
DCVC Bio invests in Life Sciences, Agtech and Biotechnology, and is based in California, United States. DCVC Bio is listed as a venture capital in the ConnectSafely investor database.
Which regions does DCVC Bio invest in?
DCVC Bio invests across United States.
What companies has DCVC Bio invested in?
DCVC Bio's portfolio includes AbCellera, Umoja Biopharma, Chroma Medicine, Elo Life Systems, MycoWorks, Sabanto and BioPhero.
Last updated · Source: ConnectSafely investor database
